PMID- 15244499
OWN - NLM
STAT- MEDLINE
DCOM- 20041221
LR  - 20181025
IS  - 1173-8804 (Print)
IS  - 1173-8804 (Linking)
VI  - 18
IP  - 4
DP  - 2004
TI  - New advances and potential therapies for the treatment of asthma.
PG  - 211-23
AB  - Asthma is a disease of the airways with an underlying inflammatory component. The 
      prevalence and healthcare burden of asthma is still rising and is predicted to 
      continue to rise in the current century. Inhaled beta(2)-adrenoceptor agonists 
      and corticosteroids form the basis of the treatments available to alleviate the 
      symptoms of asthma. There is a need for novel, safe treatments to tackle the 
      underlying inflammation that characterizes asthma pathology. Furthermore, there 
      is a requirement for new treatments to be developed as oral therapy in order to 
      alleviate patient compliance issues, especially in children. A multitude of new 
      approaches and new targets are being investigated, which may provide 
      opportunities for novel therapeutic interventions in this debilitating disease. 
      For simplicity, these approaches can be divided into two categories. The first 
      comprises therapies directed against specific components or steps seen in 
      allergic asthma. By 'components' we mean the key inflammatory cells (T cells [in 
      particular T(h)2], B cells, eosinophils, mast cells, basophils and antigen 
      presenting cells [APC]) and mediators (immunoglobulin E [IgE], cytokines, 
      histamines, leukotrienes and prostanoids) believed to be involved in the chronic 
      inflammation seen in asthma. By 'steps' we mean the allergic response, such as 
      antigen processing and presentation, T(h)2-cell activation, B-cell isotype 
      switching, mast cell involvement and airway remodeling. The other category of 
      novel approaches to disease modification in asthma encompasses general 
      anti-inflammatory therapies including phosphodiesterase 4 (PDE4) inhibitors, p38 
      mitogen-activated protein kinase (MAPK) inhibitors, peroxisome 
      proliferator-activated receptor-gamma (PPARgamma) agonists, and lipoxins.
FAU - Belvisi, Maria G
AU  - Belvisi MG
AD  - Respiratory Pharmacology Group, Cardiothoracic Surgery, National Heart and Lung 
      Institute, Faculty of Medicine, Imperial College, London, UK. 
      m.belvisi@imperial.ac.uk
FAU - Hele, David J
AU  - Hele DJ
FAU - Birrell, Mark A
AU  - Birrell MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - BioDrugs
JT  - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
JID - 9705305
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - 0 (Receptors, Chemokine)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Animals
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - *Asthma/drug therapy/physiopathology/therapy
MH  - Humans
MH  - *Immunotherapy/methods/trends
MH  - Peroxisome Proliferator-Activated Receptors/agonists
MH  - Receptors, Chemokine/antagonists & inhibitors
MH  - T-Lymphocytes/drug effects/physiology
RF  - 142
EDAT- 2004/07/13 05:00
MHDA- 2004/12/22 09:00
CRDT- 2004/07/13 05:00
PHST- 2004/07/13 05:00 [pubmed]
PHST- 2004/12/22 09:00 [medline]
PHST- 2004/07/13 05:00 [entrez]
AID - 1841 [pii]
AID - 10.2165/00063030-200418040-00001 [doi]
PST - ppublish
SO  - BioDrugs. 2004;18(4):211-23. doi: 10.2165/00063030-200418040-00001.